Compare RIO & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RIO | SNY |
|---|---|---|
| Founded | 1873 | 1994 |
| Country | United Kingdom | France |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 168.0B | 95.7B |
| IPO Year | 1995 | 2001 |
| Metric | RIO | SNY |
|---|---|---|
| Price | $83.62 | $41.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 11 |
| Target Price | ★ $103.04 | $53.61 |
| AVG Volume (30 Days) | 1.9M | ★ 3.1M |
| Earning Date | 07-29-2026 | 10-30-2026 |
| Dividend Yield | 5.48% | ★ 5.76% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.34 | $1.46 |
| Revenue Next Year | $2.43 | $6.51 |
| P/E Ratio | $15.76 | ★ $6.14 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $67.74 | $39.07 |
| 52 Week High | $112.58 | $52.68 |
| Indicator | RIO | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 19.96 | 53.26 |
| Support Level | $82.35 | $41.19 |
| Resistance Level | $100.90 | $41.88 |
| Average True Range (ATR) | 1.44 | 0.68 |
| MACD | -0.80 | 0.33 |
| Stochastic Oscillator | 6.92 | 81.74 |
Rio Tinto is a global diversified miner. Iron ore is its major commodity, with lesser contributions from copper and aluminum. Lithium, diamonds, gold, and industrial minerals are more minor contributors. The 1995 merger of RTZ and CRA, via a dual-listed structure, created the present-day company. The two operate as a single business entity, with shareholders in each company having equivalent economic and voting rights. Major assets included the Pilbara iron ore operations, a 30% stake in the Escondida copper mine, 66%-ownership of the Oyu Tolgoi copper mine in Mongolia, the Weipa and Gove bauxite mines in Australia, and six hydro-powered aluminum smelters in Canada.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest-revenue product, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.